These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. Koneczny I; Cossins J; Vincent A J Anat; 2014 Jan; 224(1):29-35. PubMed ID: 23458718 [TBL] [Abstract][Full Text] [Related]
13. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment. Cao M; Koneczny I; Vincent A Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. Phillips WD; Vincent A F1000Res; 2016; 5():. PubMed ID: 27408701 [TBL] [Abstract][Full Text] [Related]
16. Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis. Park G; Kesserwani H Cureus; 2021 Nov; 13(11):e19701. PubMed ID: 34934570 [TBL] [Abstract][Full Text] [Related]
17. Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Phillips WD; Christadoss P; Losen M; Punga AR; Shigemoto K; Verschuuren J; Vincent A Exp Neurol; 2015 Aug; 270():29-40. PubMed ID: 25542979 [TBL] [Abstract][Full Text] [Related]
18. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451 [TBL] [Abstract][Full Text] [Related]